Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis.
Irene Scala, Antonio Ciacciarelli, Virginia Cancelloni et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and individual-patient data meta-analysis evaluated the safety and efficacy of repeated intravenous thrombolysis (RIVT) for acute ischemic stroke (AIS) within 90 days of a previous treatment. In a cohort of 63 patients, 66.7% achieved favorable outcomes, with no symptomatic intracranial hemorrhages reported. The pooled odds ratio for better functional outcomes was 1.52.
Key findings
- 66.7% of patients achieved a favorable outcome after RIVT.
- No symptomatic intracranial hemorrhages occurred post-RIVT.
- Asymptomatic hemorrhages were reported in 15.9% of patients.
- Pooled odds ratio for better functional outcomes was 1.52.
Why it matters
Understanding the safety and efficacy of RIVT in recurrent AIS can inform clinical decision-making, particularly in cases where previous stroke treatment may complicate management. This evidence may challenge existing contraindications and expand treatment options.